StockNews.com Lowers Collegium Pharmaceutical (NASDAQ:COLL) to Buy

StockNews.com lowered shares of Collegium Pharmaceutical (NASDAQ:COLL) from a strong-buy rating to a buy rating in a research note issued to investors on Wednesday.

Other equities analysts have also issued reports about the company. Jefferies Financial Group restated a hold rating and set a $37.00 price target (up from $30.00) on shares of Collegium Pharmaceutical in a research report on Thursday, January 4th. Truist Financial raised their target price on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a buy rating in a report on Monday, February 26th. Piper Sandler restated an overweight rating and issued a $39.00 price objective (up previously from $37.00) on shares of Collegium Pharmaceutical in a research report on Friday, February 23rd. Finally, Needham & Company LLC reiterated a buy rating and set a $40.00 target price on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of Moderate Buy and an average target price of $39.00.

Collegium Pharmaceutical Stock Performance

COLL stock opened at $37.51 on Wednesday. Collegium Pharmaceutical has a one year low of $20.83 and a one year high of $40.95. The company has a market capitalization of $1.23 billion, a PE ratio of 31.79 and a beta of 1.06. The company’s 50 day moving average price is $37.56 and its two-hundred day moving average price is $31.84. The company has a debt-to-equity ratio of 2.48, a quick ratio of 1.10 and a current ratio of 1.17.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.25. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. The company had revenue of $149.75 million for the quarter, compared to analysts’ expectations of $147.66 million. As a group, analysts predict that Collegium Pharmaceutical will post 5.63 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new position in shares of Collegium Pharmaceutical during the 3rd quarter worth approximately $221,000. Strs Ohio raised its holdings in Collegium Pharmaceutical by 1,650.0% in the third quarter. Strs Ohio now owns 21,000 shares of the specialty pharmaceutical company’s stock worth $469,000 after purchasing an additional 19,800 shares in the last quarter. Inspire Investing LLC lifted its position in Collegium Pharmaceutical by 3.2% during the third quarter. Inspire Investing LLC now owns 27,840 shares of the specialty pharmaceutical company’s stock valued at $622,000 after buying an additional 873 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of Collegium Pharmaceutical by 1,019.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 41,670 shares of the specialty pharmaceutical company’s stock valued at $931,000 after buying an additional 37,946 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its position in shares of Collegium Pharmaceutical by 0.8% in the 3rd quarter. Los Angeles Capital Management LLC now owns 76,876 shares of the specialty pharmaceutical company’s stock worth $1,718,000 after buying an additional 585 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.